Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer

Authors: Fangyong Lei, Longjuan Zhang, Xinghua Li, Xi Lin, Shu Wu, Fengyan Li, Junling Liu

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Prostate tumor overexpressed 1 (PTOV1) was demonstrated to play an important role in cancer progression and was correlated with unfavorable clinical outcome. However, the clinical role of PTOV1 in cancer remains largely unknown. This study aimed to investigate the expression and clinicopathological significance of PTOV1 in breast cancer.

Methods

The mRNA and protein expression levels of PTOV1 were analyzed in 12 breast cancer cell lines and eight paired breast cancer tumors by semi-quantitative real time-PCR and western blotting, respectively. Immunohistochemistry was performed to assess PTOV1 protein expression in 169 paraffin-embedded, archived breast cancer samples. Survival analysis and Cox regression analysis were performed to investigate the clinicopathological significance of PTOV1 expression.

Results

Our data revealed that PTOV1 was frequently overexpressed in breast cancer cell lines compared to normal human breast epithelial cells and in primary breast cancer samples compared to adjacent noncancerous breast tissues, at both the mRNA and protein levels. Moreover, high expression of PTOV1 in breast cancer is strongly associated with clinicopathological characteristics and estrogen receptor expression status (P = 0.003). Breast cancer patients with higher PTOV1 expression had substantially shorter survival times than patients with lower PTOV1 expression (P < 0.001). Univariate and multivariate analysis revealed that PTOV1 might be an independent prognostic factor for breast cancer patients (P = 0.005).

Conclusions

Our study showed that PTOV1 is upregulated in breast cancer cell lines and clinical samples, and its expression was positively associated with progression and aggressiveness of breast cancer, suggesting that PTOV1 could serve as an independent prognostic marker.
Appendix
Available only for authorised users
Literature
1.
Bombonati A, Sgroi DC: The molecular pathology of breast cancer progression. J Pathol. 2011, 223: 307-317.CrossRefPubMed
2.
Rebecca S, Deepa N, Ahmedin J: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63: 11-30.CrossRef
3.
Benedit P, Paciucci R, Thomson TM, Valeri M, Nadal M, Càceres C, de Torres I, Estivill X, Lozano JJ, Morote J, Reventós J: PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks. Oncogene. 2001, 20: 1455-1464.CrossRefPubMed
4.
Yousef GM, Luo LY, Diamandis EP: Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res. 1999, 19: 2843-2852.PubMed
5.
Schierup MH, Mailund T, Li H, Wang J, Tjønneland A, Vogel U, Bolund L, Nexø BA: Haplotype frequencies in a sub-region of chromosome 19q13.3, related to risk and prognosis of cancer, differ dramatically between ethnic groups. BMC Med Genet. 2009, 10: 20-CrossRefPubMedPubMedCentral
6.
Fernández S, Mosquera JL, Alaña L, Sanchez-Pla A, Morote J, Ramón Y, Cajal S, Reventós J, de Torres I, Paciucci R: PTOV1 is overexpressed in human high-grade malignant tumors. Virchows Arch. 2011, 458: 323-330.CrossRefPubMed
7.
Santamaría A, Castellanos E, Gómez V, Benedit P, Renau-Piqueras J, Morote J, Reventós J, Thomson TM, Paciucci R: PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts. Mol Cell Biol. 2005, 25: 1900-1911.CrossRefPubMedPubMedCentral
8.
Santamaría A, Fernández PL, Farré X, Benedit P, Reventós J, Morote J, Paciucci R, Thomson TM: PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle. Am J Pathol. 2003, 162: 897-905.CrossRefPubMedPubMedCentral
9.
Youn HS, Park UH, Kim EJ, Um SJ: PTOV1 antagonizes MED25 in RAR transcriptional activation. Biochem Biophys Res Commun. 2011, 404: 239-244.CrossRefPubMed
10.
Marqués N, Sesé M, Cánovas V, Valente F, Bermudo R, de Torres I, Fernández Y, Abasolo I, Fernández PL, Contreras H, Castellón E, Celià-Terrassa T, Méndez R, Ramón Y, Cajal S, Thomson TM, Paciucci R: Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1. Oncogene. 2014, 33: 1124-1134.CrossRefPubMed
11.
Li J, Zhang N, Song LB, Liao WT, Jiang LL, Gong LY, Wu J, Yuan J, Zhang HZ, Zeng MS, Li M: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res. 2008, 14: 3319-3326.CrossRefPubMed
12.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 2001, 25: 402-408.CrossRefPubMed
13.
Gong H, Song L, Lin C, Liu A, Lin X, Wu J, Li M, Li J: Downregulation of miR-138 sustains NF-κB activation and promotes lipid raft formation in esophageal squamous cell carcinoma. Clin Cancer Res. 2013, 19: 1083-1093.CrossRefPubMed
14.
Song L, Gong H, Lin C, Wang C, Liu L, Wu J, Li M, Li J: Flotillin-1 promotes tumor necrosis factor-α receptor signaling and activation of NF-κB in esophageal squamous cell carcinoma cells. Gastroenterology. 2012, 143: 995-1005.CrossRefPubMed
15.
Li H, Wang RM, Liu SG, Zhang JP, Luo JY, Zhang BJ, Zhang XG: Abnormal expression of FLOT1 correlates with tumor progression and poor survival in patients with non-small cell lung cancer. Tumour Biol. 2013, in press
16.
Lin C, Wu Z, Lin X, Yu C, Shi T, Zeng Y, Wang X, Li J, Song L: Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res. 2011, 17: 3089-3099.CrossRefPubMed
17.
Zhang Y, Pu X, Shi M, Chen L, Qian L, Song Y, Yuan G, Zhang H, Yu M, Hu M, Shen B, Guo N: c-Jun, a crucial molecule in metastasis of breast cancer and potential target for biotherapy. Oncol Rep. 2007, 18: 1207-1212.PubMed
18.
Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, Lisanti MP, Pestell RG: c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem. 2010, 285: 8218-8226.CrossRefPubMedPubMedCentral
19.
Mazzucchelli R, Scarpelli M, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Montironi R: Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate: additional evidence linking (AAH) to adenocarcinoma. Cell Oncol (Dordr). 2013, 36: 37-42.CrossRef
20.
Morote J, Fernández S, Alaña L, Iglesias C, Planas J, Reventós J, Ramón Y, Cajal S, Paciucci R, de Torres IM: PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy. Clin Cancer Res. 2008, 14: 2617-2622.CrossRefPubMed
21.
Williams C, Lin CY: Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. Ecancermedicalscience. 2013, 7: 370-PubMedPubMedCentral
22.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol. 2007, 25: 3846-3852.CrossRefPubMed
23.
Thomson CS, Twelves CJ, Mallon EA, Leake RE, Scottish Cancer Trials Breast Group; Scottish Cancer Therapy Network: Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast. 2002, 11: 419-429.CrossRefPubMed
24.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS: Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors—International Breast Cancer Study Group. J Clin Oncol. 2008, 26: 1404-1410.CrossRefPubMed
25.
Horwitz KB, McGuire WL: Estrogen control of progesterone receptor induction in human breast cancer: role of nuclear estrogen receptor. Adv Exp Med Biol. 1979, 117: 95-110.CrossRefPubMed
26.
Massarweh S, Schiff R: Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006, 13 (Suppl 1): 15-24.CrossRef
Metadata
Title
Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer
Authors
Fangyong Lei
Longjuan Zhang
Xinghua Li
Xi Lin
Shu Wu
Fengyan Li
Junling Liu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-457

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Reviewer acknowledgement

Reviewer acknowledgement 2013

Research article

Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

Research article

A longitudinal study investigating quality of life and nutritional outcomes in advanced cancer patients receiving home parenteral nutrition

Research article

Nitidine chloride inhibits hepatic cancer growth via modulation of multiple signaling pathways

Research article

Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer

Research article

Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits